InflaRx NV
IFRX
Company Profile
Business description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Contact
Winzerlaer Strasse 2
Jena07745
DEUT: +49 3641508180
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
74
Stocks News & Analysis
stocks
The ‘other’ AI chip behemoth that might just be getting started
The magnitude of growth at Broadcom continues to astound us.
stocks
Why ANZ changes aren’t just about cutting costs
The banking major needs to prevent key product offerings from falling further behind the competition.
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,095.20 | 28.80 | 0.32% |
| CAC 40 | 7,761.32 | 11.93 | 0.15% |
| DAX 40 | 23,632.95 | 85.50 | -0.36% |
| Dow JONES (US) | 45,490.92 | 220.42 | -0.48% |
| FTSE 100 | 9,225.39 | 17.14 | -0.19% |
| HKSE | 26,200.26 | 262.13 | 1.01% |
| NASDAQ | 21,886.06 | 6.57 | 0.03% |
| Nikkei 225 | 43,837.67 | 378.38 | 0.87% |
| NZX 50 Index | 13,276.24 | 22.51 | 0.17% |
| S&P 500 | 6,532.04 | 19.43 | 0.30% |
| S&P/ASX 200 | 8,830.40 | 40.00 | 0.46% |
| SSE Composite Index | 3,812.22 | 4.93 | 0.13% |